Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
| Autor: | Yaya Chu, Sanghoon Lee, Tishi Shah, Changhong Yin, Matthew Barth, Rodney R. Miles, Janet Ayello, Erin Morris, Lauren Harrison, Carmella Van de Ven, Paul Galardy, Stanton C. Goldman, Megan S. Lim, Michelle Hermiston, Linda M. McAllister-Lucas, Lisa Giulino-Roth, Sherrie L. Perkins, Mitchell S. Cairo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | OncoImmunology, Vol 8, Iss 1 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2162-402X 2162402X |
| DOI: | 10.1080/2162402X.2018.1512455 |
| Popis: | Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton’s tyrosine kinase (BTK) is activated following B-cell receptor stimulation and in part regulates normal B-cell development. Ibrutinib, a selective and irreversible BTK inhibitor, has been efficacious in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and marginal zone lymphoma. In this study, we investigated the efficacy of ibrutinib alone and in selective adjuvant combinations against BL in-vitro and in a human BL xenografted immune-deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mouse model. Our data demonstrated that phospho-BTK level was significantly reduced in BL cells treated with ibrutinib (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|